Archives202520242023202220212020201920182017201620152014201320122011 December 19, 2019Admission to trading on Euronext Growth Brussels Read More December 17, 2019Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Read More December 13, 2019Dual listing on Euronext growth Brussels Read More December 11, 2019Share price volatility Read More December 03, 2019ImmuPharma to present at Biotech Showcase™ 2020 in San Francisco Read More December 02, 2019TR1 – Notification of major interest in shareholdings Read More November 28, 2019ImmuPharma and Avion Pharmaceuticals sign exclusive licence Read More September 30, 2019INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2019 Read More July 04, 2019TR1 – Notification of Major Interest – Lanstead Capital Investors Read More July 02, 2019TR1 – Notification of Major Shareholding Read More June 28, 20192019 Annual General Meeting – All resolutions passed Read More June 28, 2019Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Read More 12
December 17, 2019Publication of Information Note – In advance to admission to trading on Euronext Growth Brussels Read More
June 28, 2019Primary endpoint successfully met from the open label extension study evaluating safety and tolerability from the Pivotal Phase III trial of Lupuzor™ in patients with Systemic Lupus Erythematosus (“Lupus”) Read More
